title: [Effect of endotelioprotectors on the tone of pulmonary arteries and bronchi in the model of obstructive lung pathology].
abstract: In the model of chronic obstructive pulmonary disease (COPD), produced in rats by 60-day exposure to nitrogen dioxide, the effect of drugs with endotelioprotector properties (sulodexide and rosuvastatin) on the functional state of small pulmonary arteries and bronchi was studied. We evaluated the contractile activity of smooth muscle strips of the bronchi caused by stimulation of the nerves or muscles, and changes in tone of isolated pulmonary artery rings at the application of reagents-vasodilators. The use of sulodexide promoted restoration NO-dependent mechanism of vasodilatation and improved β-adrenergic regulation of the pulmonary artery tone. The use of rosuvastatin had no effect on the dilator activity of pulmonary arteries. Both drugs improved the functional status of the bronchial smooth muscles and intrabronchial nervous system that controls the contractile activity of smooth muscle structures of the airways. The results of the study suggest that the one-way relaxing effect of sulodexide on pulmonary arterial and bronchial smooth muscles enables the recovery of coordinated regulation of the tone of these structures, which is essential for maintaining the optimal ratio of ventilation and pulmonary blood flow for efficient gas exchange.
authors.forename: N A
authors.initials: NA
authors.lastname: Kuzubova
authors.forename: A N
authors.initials: AN
authors.lastname: Fedin
authors.forename: E S
authors.initials: ES
authors.lastname: Lebedeva
authors.forename: O N
authors.initials: ON
authors.lastname: Titova
mesh_terms: D000818:Animals; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects; D005464:Fluorobenzenes / Q000494:pharmacology*; D006025:Glycosaminoglycans / Q000494:pharmacology*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009585:Nitrogen Dioxide; D020011:Protective Agents / Q000494:pharmacology*; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D005464:Fluorobenzenes; D006025:Glycosaminoglycans; D020011:Protective Agents; D011743:Pyrimidines; D013449:Sulfonamides; C007858:glucuronyl glucosamine glycan sulfate; D000068718:Rosuvastatin Calcium; D009585:Nitrogen Dioxide